All In Biotech

Drug Trial Radar · NCT07876804

A Long-term Follow-up Study in Male Participants With X-linked Myotubular Myopathy Treated With ASP2957

A Long-term Study of Young Boys With X-linked Myotubular Myopathy Who Had Previously Received ASP2957

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Oct 31, 2026

Primary completion

Jul 31, 2032

Study completion Jul 31, 2032

Sponsor

Lead sponsor
Astellas Gene TherapiesAstellas (ALPMY)
Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, up to 36 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

X-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no approved therapies for XLMTM. The protein myotubularin is needed for muscle development, movement and breathing. A gene called MTM1 tells the body to make myotubularin. XLMTM is caused by changes, or mutations, in the MTM1 gene. Changes in the MTM1 gene cause low or no levels of myotubularin to be made, so the muscles do not work properly. Gene therapy is a way of getting a healthy copy of a gene into the body. This allows the body's cells to make a normal protein that may reduce disease symptoms. Researchers have developed ASP2957 to get a healthy MTM1 gene into the body. This could help improve muscle development and function in young children with XLMTM. A single dose of ASP2957 has previously been given to young boys in an earlier study, but health authorities require up to a 5-year follow-up of the boys. This study is a long-term follow-up study of the young boys with XLMTM who previously received ASP2957 in an earlier study. They won't receive ASP2957 in this long-term study. The main aims of the study is recording medical problems that happen during this study after receiving ASP2957 (in the earlier study), and whether they were caused by ASP2957 or not. This may include abnormal results from blood tests, medical examinations and imaging to check heart health. They may continue to take medicines that lower their immune system from an earlier study. These help to avoid a reaction to ASP2957.

Conditions

  • X-linked Myotubular Myopathy

Interventions

  • ASP2957Drug

    Participants who have received ASP2957 in Astellas sponsored study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to 5 years
  2. Number of participants with serious adverse events (SAEs)Time frame: Up to 5 years
  3. Number of participants with adverse events of special interest (AESIs)Time frame: Up to 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.